These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23644971)

  • 61. Helicobacter pylori infection in childhood: transmission and role of antibiotics.
    Rothenbacher D; Brenner H
    Gastroenterology; 2002 Apr; 122(4):1190; author reply 1190-1. PubMed ID: 11910381
    [No Abstract]   [Full Text] [Related]  

  • 62. Helicobacter pylori infection in Egypt; a very common disease with low evidence based clinical practice.
    Alboraie M; Elhossary W
    Arab J Gastroenterol; 2018 Mar; 19(1):49. PubMed ID: 29523471
    [No Abstract]   [Full Text] [Related]  

  • 63. [Are we doing the right thing with Helicobacter pylori?].
    López-Colombo A
    Rev Gastroenterol Mex; 2012; 77(3):106-7. PubMed ID: 22921102
    [No Abstract]   [Full Text] [Related]  

  • 64. Helicobacter pylori Resistance: A Medical Predictive Factor of Response.
    Ribaldone DG; Fagoonee S
    Arch Iran Med; 2019 Apr; 22(4):221. PubMed ID: 31126184
    [No Abstract]   [Full Text] [Related]  

  • 65. Belgian consensus for Helicobacter pylori management 2023.
    Garcés-Duran R; Kindt S; Kotilea K; François S; Rasschaert G; Smet A; Hauser B; Driessen A; Nkuize M; Burette A; Lamy V; Bontems P; Louis H; Ntounda R; Miendje Deyi VY; Mana F
    Acta Gastroenterol Belg; 2023; 86(1):74-91. PubMed ID: 36842178
    [No Abstract]   [Full Text] [Related]  

  • 66. Helicobacter pylori: Indian perspective.
    Patnayak R; Jena A; Reddy VR; Asha T
    Saudi J Gastroenterol; 2015; 21(1):55. PubMed ID: 25672241
    [No Abstract]   [Full Text] [Related]  

  • 67. Emerging parameters relevant to the management of antimicrobial-resistant Helicobacter pylori infection.
    Kountouras J; Doulberis M; Polyzos SA; Kazakos E; Vardaka E; Tzitiridou-Chatzopoulou M; Chatzopoulos D; Liatsos C; Kyriakopoulos A; Papaefthymiou A
    Intern Med J; 2022 Sep; 52(9):1654-1655. PubMed ID: 36100561
    [No Abstract]   [Full Text] [Related]  

  • 68. In response to "Conclusive strategies for therapy and virotyping of Helicobacter pylori".
    Alvi A
    Saudi J Gastroenterol; 2014; 20(5):326. PubMed ID: 25384332
    [No Abstract]   [Full Text] [Related]  

  • 69. Treatment considerations in Helicobacter pylori management.
    Yang JC; Kao JY
    Aliment Pharmacol Ther; 2022 Jan; 55 Suppl 1():S22-S28. PubMed ID: 34989432
    [No Abstract]   [Full Text] [Related]  

  • 70. Conclusive strategies for therapy and virotyping of Helicobacter pylori.
    Abadi AT; Mobarez AM
    Saudi J Gastroenterol; 2014; 20(5):325. PubMed ID: 25253371
    [No Abstract]   [Full Text] [Related]  

  • 71. The role of interleukin 10 in the associations between migraine and Helicobacter pylori infection.
    Kang JW; Shin YI
    Pain Physician; 2013; 16(4):E450. PubMed ID: 23877472
    [No Abstract]   [Full Text] [Related]  

  • 72. Current approach to fosfomycin: From bench to bedside.
    Candel FJ; Cantón R
    Enferm Infecc Microbiol Clin (Engl Ed); 2019 Jan; 37(1):1-3. PubMed ID: 30360920
    [No Abstract]   [Full Text] [Related]  

  • 73. Recent developments in the field of phosphonic acid antibiotics.
    Neuman M
    J Antimicrob Chemother; 1984 Oct; 14(4):309-11. PubMed ID: 6501127
    [No Abstract]   [Full Text] [Related]  

  • 74. Guide regarding choice of second-line therapy to obtain a high cumulative cure rate.
    Graham DY; Calvet X
    Helicobacter; 2012 Aug; 17(4):243-5. PubMed ID: 22759322
    [No Abstract]   [Full Text] [Related]  

  • 75. In response.
    Faraji F
    Pain Physician; 2013; 16(2):E121. PubMed ID: 23631015
    [No Abstract]   [Full Text] [Related]  

  • 76. The Impact of Fosfomycin on Gram Negative Infections: A Comprehensive Review.
    Dubey S; Siddiqui AH; Sharma M
    Indian J Microbiol; 2024 Sep; 64(3):846-858. PubMed ID: 39282196
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Synergistic activity and molecular modelling of fosfomycin combinations with some antibiotics against multidrug resistant Helicobacter pylori.
    Abouwarda AM; Ismail TA; Abu El-Wafa WM; Faraag AHI
    World J Microbiol Biotechnol; 2022 Apr; 38(6):102. PubMed ID: 35486219
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Oral and intravenous fosfomycin in complicated urinary tract infections.
    López-Montesinos I; Horcajada JP
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):37-44. PubMed ID: 31131591
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Fosfomycin.
    Falagas ME; Vouloumanou EK; Samonis G; Vardakas KZ
    Clin Microbiol Rev; 2016 Apr; 29(2):321-47. PubMed ID: 26960938
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Three unsuccessful treatments of Helicobacter pylori infection by a highly virulent strain with quadruple antibiotic resistance.
    Boyanova L; Evstatiev I; Yordanov D; Markovska R; Mitov I
    Folia Microbiol (Praha); 2016 Jul; 61(4):307-10. PubMed ID: 26634607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.